OTCMKTS:DDXSQ

Diadexus Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume100 shs
Average Volume5,050 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-3.56

Competitors

Diadexus (OTCMKTS:DDXSQ) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying DDXSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Diadexus, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Diadexus (OTCMKTS:DDXSQ) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings for Diadexus and Acusphere, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Diadexus0000N/A
Acusphere0000N/A

Profitability

This table compares Diadexus and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiadexusN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares Diadexus and Acusphere's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiadexusN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Risk & Volatility

Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Summary

Acusphere beats Diadexus on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Affymax and Diadexus' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
DiadexusN/AN/AN/AN/AN/A

Profitability

This table compares Affymax and Diadexus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
DiadexusN/AN/AN/A

Volatility & Risk

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Affymax and Diadexus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Diadexus0000N/A

Summary

Affymax beats Diadexus on 1 of the 1 factors compared between the two stocks.

Diadexus (OTCMKTS:DDXSQ) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Diadexus and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiadexusN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Volatility & Risk

Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Earnings & Valuation

This table compares Diadexus and ARYx Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiadexusN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Diadexus and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Diadexus0000N/A
ARYx Therapeutics0000N/A

Summary

ARYx Therapeutics beats Diadexus on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for AtheroNova and Diadexus, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
Diadexus0000N/A

Profitability

This table compares AtheroNova and Diadexus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
DiadexusN/AN/AN/A

Volatility and Risk

AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and Diadexus' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
DiadexusN/AN/AN/AN/AN/A

Summary

Diadexus beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares China Botanic Pharmaceutical and Diadexus' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
DiadexusN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for China Botanic Pharmaceutical and Diadexus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Diadexus0000N/A

Profitability

This table compares China Botanic Pharmaceutical and Diadexus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
DiadexusN/AN/AN/A

Risk and Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats Diadexus on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Diadexus (OTCMKTS:DDXSQ) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for China Dongsheng International and Diadexus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
Diadexus0000N/A

Earnings & Valuation

This table compares China Dongsheng International and Diadexus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
DiadexusN/AN/AN/AN/AN/A

Profitability

This table compares China Dongsheng International and Diadexus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
DiadexusN/AN/AN/A

Volatility and Risk

China Dongsheng International has a beta of 13.38, indicating that its share price is 1,238% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, indicating that its share price is 456% less volatile than the S&P 500.

Summary

China Dongsheng International beats Diadexus on 1 of the 1 factors compared between the two stocks.


Diadexus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.04flat$0.00N/A0.00
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Up
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Gap Down
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.91flat$0.00N/A0.00Gap Down
HRBR
Harbor Diversified
0.0$1.93flat$0.00$263.61 million0.00High Trading Volume
Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.06flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00Gap Down
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.02flat$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.